Linagen 5 Tablet contains Linagliptin 5 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin enhances the incretin system by inhibiting the DPP-4 enzyme, thereby increasing the levels of active incretin hormones such as GLP-1 and GIP. This mechanism results in glucose-dependent stimulation of insulin secretion and suppression of glucagon release, contributing to improved glycemic control without causing significant hypoglycemia. Linagen 5 is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents including metformin, sulfonylureas, or insulin. The drug is characterized by its favorable pharmacokinetic profile, including once-daily dosing and minimal renal excretion, making it suitable for patients with varying degrees of renal impairment without dose adjustment. Common adverse effects are generally mild and may include nasopharyngitis, headache, and upper respiratory tract infections. Linagen 5 should be used cautiously in patients with a history of pancreatitis. Regular monitoring of blood glucose levels and periodic assessment of renal function are recommended during therapy to ensure optimal safety and efficacy.